MDMA, magic mushrooms could be the hottest entry in psychiatry, researchers hopeful Psychedelics could be the newest entry to psychiatric therapies as researchers exploring the therapeutic prowess of the compounds are optimistic about its impact in treating post-traumatic stress disorder. advertisement Image for Representation. (Photo: Reuters) Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), is exploring the healing power of compounds such as LSD, Ecstasy and magic mushrooms in treating mental health disorders in patients, amid anti-drug campaigns that criminalise the use of such substances. The first Phase 3 clinical trial of Doblin's study conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought substantial relief to patients with severe post-traumatic stress disorder, the New York Times reported. Nature Medicine is also expected to publish results of his lab study on MDMA soon - which could be a major push for Doblin in his fight for mainstream acceptance of psychedelics.